SCHEMBL27118281

SCHEMBL27118281

COc1ncccc1-c1ccc(S(=O)(=O)Nc2cccc3cnn(C)c23)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 9/20 0.44
▸ GLO1 Q04760 4/20 0.44
▸ PTGES2 Q9H7Z7 1/20 0.44
▸ KMT2A Q03164 6/20 0.40
▸ TDP1 Q9NUW8 6/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ AGTR1 P30556 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ MITF O75030 1/20 0.40
▸ S1PR4 O95977 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ S1PR1 P21453 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CKS1B P61024 1/20 0.40
▸ SKP2 Q13309 1/20 0.40
▸ EIF2AK3 Q9NZJ5 1/20 0.39
▸ MEN1 O00255 5/20 0.39
▸ SCN9A Q15858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30846320 1.00 SLC40A1 (0.44) SLC40A1GLO1PTGES2KMT2ATDP1
SCHEMBL27118022 0.88 SLC40A1 (0.45) SLC40A1GLO1KMT2ATDP1LMNA
SCHEMBL30846219 0.88 SLC40A1 (0.45) SLC40A1GLO1KMT2ATDP1LMNA
SCHEMBL27119247 0.87 SLC40A1 (0.43) SLC40A1GLO1KMT2ATDP1LMNA
SCHEMBL30846347 0.87 SLC40A1 (0.43) SLC40A1GLO1KMT2ATDP1LMNA
SCHEMBL27118146 0.86 EIF2AK3 (0.39) SLC40A1GLO1PTGES2KMT2ATDP1
SCHEMBL27119249 0.85 SLC40A1 (0.41) SLC40A1GLO1KMT2ATDP1LMNA
SCHEMBL30846290 0.85 SLC40A1 (0.41) SLC40A1GLO1KMT2ATDP1LMNA
SCHEMBL27118385 0.83 SLC40A1 (0.44) SLC40A1GLO1KMT2ATDP1LMNA
SCHEMBL27123001 0.82 SLC40A1 (0.40) SLC40A1GLO1KMT2ATDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B SLC40A1 816/4885GLO1 3644/4885PTGES2 2085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback